Epidermolysis Bullosa Therapeutics Market Size 2021, Industry Analysis by Device Type, Application, Growing Demand, Business Insight, Top Companies, Regional Overview

Epidermolysis Bullosa Therapeutics Market, by Drugs (EB-101, Oleogel-S10 and Others), and by Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis 2018 – 2026

Epidermolysis Bullosa (EB) is referred to a genetic skin tissue disorder, which is rare. People having EB possess fragile skin that is vulnerable to blisters causing difficult to heal wounds. Symptoms associated with the disorder are, skin blistering, loss or deformity of toenails and fingernails, internal blistering such as in the esophagus, stomach, throat, urinary tract and intestines, thickening of palm and sole skin (hyperkeratosis), scarring, and scalp blistering, along with loss of hair loss (scarring alopecia). 

Get PDF Brochure Here

Global Epidermolysis Bullosa Therapeutics Market Drivers

Advancement of several drug pipelines to treat EB is the key factor expected to fuel growth of the global epidermolysis bullosa therapeutics market over the forecast period. For instance, the Fibrocell Technologies, Inc. is going through clinical trials for its FCX-007 drug to treat EB. The drug is currently under phase II clinical trial and is expected to finish by December 2033.

Furthermore, the TWi Biotechnology, Inc. is performing clinical trial in phase II for the AC-203 drug for the treatment of EB skin lesions, which is expected to be finished by February 2019. Moreover, Amryt Research Limited, is regulating phase III clinical trial for its Oleogel-S10 drug, which is aimed to treat EB wounds that is projected to be over by September 2020.

Moreover, Abeona Therapeutics Inc., in May 2018, declared revised clinical data of the EB-101’s Phase I/II clinical trial, which is cell therapy of gene-corrected skin graft for patients having recessive dystrophic epidermolysis bullosa (RDEB). The EB-101, in January 2018, has been given the designation of Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric Disease Designation and Orphan Drug Designation, in 2017, by the U.S. Food and Drug Administration (US FDA) and the European Medicines Agency (EMA). Hence, growing amount of drugs within the pipeline is offering lucrative opportunities for companies in the market.

Global Epidermolysis Bullosa Therapeutics Market Restraints

Drug withdrawals that achieve failure in meeting expectations is expected to hamper the global epidermolysis bullosa therapeutics market over the forecast period. For instance, Rival Amicus Therapeutics, in September 2017, withdrew its drug AP101 that was in the clinical study of phase III. The drug AP101 was a water-based cream that is just supposed to be put on when changing dressings every 3-4 days, as suggested for patients of EB. Water based cream of this kind needed daily change of dressings in patients and the firm indicated this to be the reason behind it failing to achieve target of wound closure in three months in patients.

Global Epidermolysis Bullosa Therapeutics Market – Regional Analysis

Based on geography, the global epidermolysis bullosa therapeutics market is segregated into North America, Europe, Latin America, Asia Pacific, Africa and Middle East.

North America is expected to foresee growth within the global epidermolysis bullosa therapeutics market over the forecast period, due to key players adopting strategies of inorganic growth. For instance, Amicus Therapeutics, a biotechnologcal company developing drugs of orphan diseases, in August 2015, acquired a firm that develops innovative therapies to treat diseases – Scioderm, Inc. The acquisition aims at accelerating clinical development of Amicus Therapeutics’ Zorblisa, drug that is undergoing preclinical investigation of commercialization.

Key players adopting strategies including collaborations in the region of Asia Pacific, is expected to propel the global epidermolysis bullosa therapeutics market growth in this region. For instance, RegeneRx Biopharmaceuticals, Inc., in August 2018, along with Korea-based YuYang DNU signed a joint venture for developing the product- RGN-137 globally for orphan indication and epidermolysis bullosa (EB) that is undergoing preclinical study. Moreover, YuYang will be investing over US$17.8 Mn in cash for the clinical development of this drug.

Global Epidermolysis Bullosa Therapeutics Market – Taxonomy

Based on Drugs

• Oleogel-S10

• EB-101

• Others

Based on Region

• North America

• Asia Pacific

• Europe

• Africa

• Latin America

• Middle East

Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/2214

Epidermolysis Bullosa Therapeutics Market – Competitive Landscape

Key players functioning in the global prosthetic liners market consists of Birken AG, Fibrocell Science, Inc., RegeneRx Biopharmaceuticals, Inc., GlaxoSmithKline Plc., InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., Scioderm, Inc., Stratatech Corporation, TWi Biotechnology Inc., Amryt Research Limited, and WAVE Life Sciences Ltd.

Main points in Epidermolysis Bullosa Therapeutics Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Epidermolysis Bullosa Therapeutics Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Epidermolysis Bullosa Therapeutics Industry Impact

Chapter 2 Global Epidermolysis Bullosa Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Epidermolysis Bullosa Therapeutics (Volume and Value) by Type
2.3 Global Epidermolysis Bullosa Therapeutics (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Epidermolysis Bullosa Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Epidermolysis Bullosa Therapeutics Market Analysis
Chapter 6 East Asia Epidermolysis Bullosa Therapeutics Market Analysis
Chapter 7 Europe Epidermolysis Bullosa Therapeutics Market Analysis
Chapter 8 South Asia Epidermolysis Bullosa Therapeutics Market Analysis
Chapter 9 Southeast Asia Epidermolysis Bullosa Therapeutics Market Analysis
Chapter 10 Middle East Epidermolysis Bullosa Therapeutics Market Analysis
Chapter 11 Africa Epidermolysis Bullosa Therapeutics Market Analysis
Chapter 12 Oceania Epidermolysis Bullosa Therapeutics Market Analysis
Chapter 13 South America Epidermolysis Bullosa Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Epidermolysis Bullosa Therapeutics Business
Chapter 15 Global Epidermolysis Bullosa Therapeutics Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com